Jam

HyOrc Corporation (OTC: ASPZ) is expanding globally with hydrogen rail systems, green methanol production, and modular off-grid energy solutions. Its hybrid technology merges hydrogen combustion with organic Rankine cycle turbines, offering diesel alternatives at cost parity without subsidies. Key strengths include a diversified project pipeline, focus on decarbonization markets (EU/UK), and planned OTCQB uplisting. Challenges encompass scaling risks, unproven technical differentiation, and undisclosed partnership details. Analysts highlight potential supply chain disruption through containerized systems, while HyOrc targets rail operators and industries needing emissions-compliant solutions. The company emphasizes an asset-light, licensing-based model amid tightening global emissions regulations.

Y-mAbs Therapeutics presented Phase 1 Trial 1001 data for its GD2-SADA PRIT therapy at the Neuroblastoma Research Meeting, targeting recurrent/refractory GD2-positive solid tumors (neuroblastoma, lung cancer, sarcoma, melanoma). The two-step approach combines non-radioactive GD2-SADA proteins with Lutetium-177 to selectively irradiate tumors. Following Part A dose optimization, preliminary safety/efficacy results will be disclosed May 28th. If proven effective, this precision radiotherapy platform could address high-unmet needs across oncology markets, positioning YMAB for potential partnerships in the $6.8B radiopharma sector.

Atico Mining secured a 30-year concession for Colombia’s El Roble copper-gold mine, stabilizing operations until 2055 and releasing $10M worth of pledged copper concentrate for immediate liquidity. The deal resolves a $12M arbitration liability, with $3M paid and $10.7M deferred to 2025–2026, aligned with projected cash flows. It transitions regulatory terms to modern mining codes but adds community development and state compensation costs. CEO Ganoza emphasized the concession’s role in shifting focus to growth and exploration. Risks include copper price volatility and inflation-adjusted settlement increases. The mine remains central to Atico’s revenue amid Colombia’s evolving mining policies.

COSCIENS Biopharma faces activist pressure as investors Goodwood Fund and Puccetti Funds Management nominate six board directors, signaling a push for strategic changes. The firm, known for plant-based innovations in skincare (e.g., Aveeno’s oat compounds) and diagnostics like macimorelin, is evaluating the proposal amid scrutiny over its clinical trial pace, particularly for its cholesterol drug candidate. Balancing cosmeceutical growth with pharmaceutical ambitions, COSCIENS confronts investor demands for accelerated commercialization and governance reforms. Challenges include trial uncertainties for its growth hormone diagnostic and market pressures, with leadership decisions likely to shape its trajectory in competitive biopharma markets.

Axcap Ventures (CSE: AXCP) acquired Carlyle Commodities’ Newton Gold Project in British Columbia for up to $8 million, gaining full ownership of the 23,003-hectare property with an inferred resource of 843,000 oz gold and 4.5 million oz silver. The deal includes $500,000 cash, 3.75 million shares, and warrants for Carlyle, plus performance-based incentives tied to resource expansion and feasibility milestones. A 2% net smelter royalty includes an option for Axcap to buy back half for $2 million. The acquisition positions Axcap to explore the underexplored Cariboo region amid high gold prices, though challenges include low 0.64 g/t grades and potential shareholder dilution. Initial drilling results are expected in late 2025.

TotalEnergies launched oil production from its Mero-4 phase in Brazil’s pre-salt Santos Basin, bolstering its low-carbon strategy. The offshore project, linked to the 180,000 b/d Alexandre de Gusmão FPSO, employs emissions-reduction technologies like gas reinjection. Combined with existing units, Mero’s total output reaches 770,000 b/d. TotalEnergies’ stake is expected to deliver 100,000 boe/d. Operated by the Libra Consortium (Petrobras, TotalEnergies, Shell, CNPC, CNOOC, and Pré-Sal Petróleo), the project aligns with the company’s 3% annual production growth target by 2030. TotalEnergies also emphasized Brazil’s role in its renewables expansion, including a 12 GW solar/wind joint venture, balancing hydrocarbon growth with sustainability goals.

Innovent Biologics’ dual GCG/GLP-1 agonist mazdutide demonstrated significant weight loss (14.84% vs. 0.47% placebo) in a Phase 3 trial (GLORY-1) with 610 Chinese adults with obesity over 48 weeks, published in *NEJM*. Over 50% achieved ≥15% weight reduction, alongside improved cardiovascular and liver health. Safety aligned with GLP-1 therapies, with transient gastrointestinal effects. This marks the first NEJM-published metabolic therapy trial from China, signaling the nation’s rise in drug innovation. Experts emphasized mazdutide’s potential in addressing China’s obesity crisis under “Healthy China 2030.” Partnerships with Eli Lilly and ongoing trials aim to expand its use in metabolic diseases.

Elektros Inc. (OTC: ELEK) announced a major lithium discovery in Sierra Leone, with grades exceeding commercial thresholds, positioning it among West Africa’s largest undeveloped deposits. The find aligns with projections of 42-fold lithium demand growth by 2040, offering potential to diversify EV supply chains amid automakers’ push for ethical sourcing. Despite Sierra Leone’s challenging business environment and Elektros’ microcap status ($12M valuation), proximity to ports and low impurity levels present advantages. Risks include unproven feasibility and infrastructure gaps. Tesla’s recent Africa-focused lithium strategy and regional patent filings hint at synergies. Success hinges on partnerships, testing, and navigating local regulations to transform the deposit into a supply chain asset.

Vail Resorts adds Austria’s Sölden to the Epic Pass for 2025/26, expanding European access. The Tyrolean resort offers 89 miles of glacier terrain, cultural attractions like the 007 ELEMENTS exhibit, and hosts premier events. Priced at $1,051 (adults) until May 26, the pass includes five days at Sölden, discounts, and access to 34 resorts across 10 European regions. New lifts will enhance glacier access next season. The partnership aligns with Vail’s 2030 net-zero goal and Europe’s travel rebound. Prices rise post-deadline, urging skiers to secure the year’s lowest rates for premium alpine destinations.

Elektros Inc. (OTC: ELEK) announced a major lithium discovery in Sierra Leone, potentially among West Africa’s largest deposits, with grades exceeding initial estimates. CEO Shlomo Bleier called it “transformative,” aligning with surging EV battery demand forecasted to grow 42-fold by 2040. The find could diversify global lithium supply dominated by Australia, Chile, and China, easing EV production bottlenecks. Despite a 23% pre-market stock surge, challenges include 3-5 years of pre-production studies, Sierra Leone’s governance risks, and volatile lithium prices. Elektros plans AI-driven exploration to expedite development, mirroring Rio Tinto’s cost-reduction strategies. The project highlights West Africa’s role in ethical, geopolitically balanced supply chains.